scholarly journals Toxoplasma gondii GRA8-derived peptide immunotherapy improves tumor targeting of colorectal cancer

Oncotarget ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 62-73 ◽  
Author(s):  
Jae-Sung Kim ◽  
Daeun Lee ◽  
Donggyu Kim ◽  
Seok-Jun Mun ◽  
Euni Cho ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Toxoplasma Gondii ◽  
Tumor Targeting ◽  
Peptide Immunotherapy

GRPR-targeted SPECT imaging using a novel bombesin-based peptide for colorectal cancer detection

2020 ◽  
Vol 8 (23) ◽  
pp. 6764-6772 ◽  
Author(s):  
Peifei Liu ◽  
Yuanbiao Tu ◽  
Ji Tao ◽  
Zicun Liu ◽  
Fang Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Detection ◽  
Tumor Targeting ◽  
Spect Imaging ◽  
Intestinal Activity ◽  
Cancer Models ◽  
Pharmacokinetic Properties ◽  
Targeting Peptide ◽  
Targeting Ability

The designed novel targeting peptide GB-6 binding to GRPR possesses more favorable pharmacokinetic properties with lower intestinal activity as well as superior tumor-targeting ability in colorectal cancer models than BBN7–14.

scholarly journals PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer

2015 ◽  
Vol 42 (11) ◽  
pp. 1700-1706 ◽  
Author(s):  
Pat Zanzonico ◽  
Jorge A. Carrasquillo ◽  
Neeta Pandit-Taskar ◽  
Joseph A. O’Donoghue ◽  
John L. Humm ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Targeting ◽  
Patient Specific ◽  
Compartmental Modeling ◽  
Quantitative Characterization ◽  
Specific Tumor

iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment

2020 ◽  
Vol 20 ◽  
Author(s):  
Li Li ◽  
Mi Yang ◽  
Rutian Li ◽  
Jing Hu ◽  
Lixia Yu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Targeting ◽  
Antitumor Effect ◽  
Plga Nanoparticles ◽  
Specific Targeting ◽  
Cancer Models ◽  
Cell Experiment ◽  
Targeting Ability ◽  
Targeting Effect ◽  
Colorectal Cancer Treatment

Objective: To explore the targeting effect of PLGA-NP and iRGD co-administration with PTX-PLGA NP (PTX-PLGA + iRGD) on colorectal cancer. Methods: Whether PLGA-NP co-administration with iRGD peptide could show effective tumor-targeting ability in contrast to with PLGA-NP in colorectal cancer mice models was evaluated. Moreover, the chemotherapeutics paclitaxel (PTX) was loaded into the PLGA-NP to impart anti-tumor efficiency to the PTX-PLGA. Whether iRGD co-administration with PTX-PLGA NP (PTX-PLGA + iRGD) in colorectal cancer models enabled PTX to achieve better anti-tumor efficiency and biocompatibility was further assessed. Results: The targeting ability of PLGA-NP was enhanced in cell experiment and colorectal cancer mice models by coadministration of iRGD. As a result, PTX-PLGA + iRGD achieved better anti-tumor efficacy than PTX and PTX-PLGA. Conlusion: The nanocarrier based on PLGA with specific targeting ability could promote the clinical application of various chemotherapeutics similar to PTX. The combination of drug-loaded nanoparticles and iRGD could develop into a promising drug delivery system.

Targeted chemoradiation for metastatic colorectal cancer: A phase I trial of oral capecitabine combined with 131I- huA33

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4078-4078
Author(s):  
R. A. Herbertson ◽  
N. Tebbutt ◽  
S. Gill ◽  
F. T. Lee ◽  
B. Chappell ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Dose Escalation ◽  
Tumor Targeting ◽  
Tumor Response ◽  
Single Photon ◽  
Phase 1 ◽  
Photon Emission ◽  
Good Tolerability ◽  
Imaging Results

4078 Background: HuA33 is a humanized antibody that targets the A33 antigen, which is highly expressed in intestinal epithelium and >95% of human colon cancers, but not other normal tissues. Previous studies have shown huA33 can target and be retained in a metastatic tumor for 6 weeks, but eliminated from normal colonocytes within days. This phase 1 study used radio-labeled huA33 in combination with capecitabine chemotherapy to target chemoradiation to metastatic colorectal cancer. Methods: The primary objective was safety and tolerability of the combination of capecitabine and 131I-huA33. Pharmacokinetics, biodistribution, immunogenicity, and tumor response were also assessed. Eligibility included measurable metastatic colorectal cancer, adequate hematological and biochemical function, and informed consent. An outpatient scout 131I-huA33 dose was followed by a single therapy infusion one week later, when capecitabine was commenced. Dose escalation occurred over 5 dose levels. Patients were evaluated weekly, with tumor response assessment at the end of the12 week trial. Tumor targeting was assessed using gamma camera and single photon emission computerized tomography (SPECT) imaging. Results: 16 patients have enrolled with 2 currently on treatment, including one in the final dose cohort. Accrual will be completed by March 2007. The dose escalation protocol was amended following 2 dose limiting toxicities in the second cohort, but subsequent cohorts demonstrated good tolerability. Biodistribution analysis demonstrated excellent tumor targeting of the known tumor sites, expected transient bowel uptake, but no other normal tissue uptake. Maximal duration of stable disease is currently 3 years. Conclusions: 131I-huA33 achieves specific targeting of radiotherapy to sites of metastasis and can be safely combined with chemotherapy. This provides an opportunity to deliver chemoradiation specifically to metastatic disease in colorectal cancer patients. [Table: see text] No significant financial relationships to disclose.

scholarly journals Increased Risk of Toxoplasma gondii Infection in Patients with Colorectal Cancer in Eastern China: Seroprevalence, Risk Factors, and a Case–Control Study

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Yang Yu ◽  
Dong Guo ◽  
Tingting Qu ◽  
Shuchao Zhao ◽  
Chang Xu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Toxoplasma Gondii ◽  
Eastern China ◽  
Stepwise Logistic Regression ◽  
Rural Residence ◽  
Igm Antibodies ◽  
Increased Risk ◽  
Significant Difference ◽  
Toxoplasma Gondii Infection

The aim of this study was to explore the epidemiology of Toxoplasma gondii infection in patients with colorectal cancer (CRC) in eastern China. Therefore, 287 primary CRC patients and 287 age-matched healthy control subjects were recruited to estimate the seroprevalence of T. gondii and identify the risk factors of infection. Enzyme-linked immunoassays were used to test for anti-T. gondii immunoglobulin G (IgG) and IgM antibodies. Forty-six (16%) samples were positive for anti-T. gondii IgG antibodies in patients with CRC, compared with 26 (9.1%) in the healthy controls, a significant difference ( P = 0.007 ). By contrast, eight (2.8%) patients tested positive for T. gondii IgM antibodies, compared with three (1.1%) in the controls, a difference that was not significant ( P = 0.13 ). Multivariable backward stepwise logistic regression analysis revealed that a rural residence (OR 2.83; 95% CI 1.15–7.01; P = 0.024 ) and treatment with chemotherapy (OR 2.16; 95% CI 1.02–4.57; P = 0.045 ) were risk factors for T. gondii infection in patients with CRC. Thus, T. gondii infection is serious in patients with CRC, and a rural residence and treatment with chemotherapy are independent risk factors for infection by this parasite. Therefore, medical professionals should be aware of this pathogen in patients with CRC, and the causes of T. gondii infection in these patients need to be explored further.

scholarly journals Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer

2020 ◽  
Vol 7 (8) ◽  
pp. 1903332 ◽  
Author(s):  
Xianli Hu ◽  
Bo Hou ◽  
Zhiai Xu ◽  
Madiha Saeed ◽  
Fang Sun ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Targeting ◽  
Combination Immunotherapy

scholarly journals Photodynamic Therapy Activity of New Porphyrin-Xylan-Coated Silica Nanoparticles in Human Colorectal Cancer

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1474 ◽  
Author(s):  
Ludovic Bretin ◽  
Aline Pinon ◽  
Soukaina Bouramtane ◽  
Catherine Ouk ◽  
Laurence Richard ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Photodynamic Therapy ◽  
Silica Nanoparticles ◽  
Solid Tumors ◽  
Tumor Targeting ◽  
Added Value ◽  
Cell Uptake ◽  
Human Colorectal Cancer ◽  
Anticancer Efficacy

Photodynamic therapy (PDT) using porphyrins has been approved for treatment of several solid tumors due to the generation of cytotoxic reactive oxygen species (ROS). However, low physiological solubility and lack of selectivity towards tumor sites are the main limitations of their clinical use. Nanoparticles are able to spontaneously accumulate in solid tumors through an enhanced permeability and retention (EPR) effect due to leaky vasculature, poor lymphatic drainage, and increased vessel permeability. Herein, we proved the added value of nanoparticle vectorization on anticancer efficacy and tumor-targeting by 5-(4-hydroxyphenyl)-10,15,20-triphenylporphyrin (TPPOH). Using 80 nm silica nanoparticles (SNPs) coated with xylan-TPPOH conjugate (TPPOH-X), we first showed very significant phototoxic effects of TPPOH-X SNPs mediated by post-PDT ROS generation and stronger cell uptake in human colorectal cancer cell lines compared to free TPPOH. Additionally, we demonstrated apoptotic cell death induced by TPPOH-X SNPs-PDT and the interest of autophagy inhibition to increase anticancer efficacy. Finally, we highlighted in vivo, without toxicity, elevated anticancer efficacy of TPPOH-X SNPs through improvement of tumor-targeting compared to a free TPPOH protocol. Our work demonstrated for the first time the strong anticancer efficacy of TPPOH in vitro and in vivo and the merit of SNPs vectorization.

scholarly journals Doxorubicin-Loaded Tumor-Targeting Peptide-Decorated Polypeptide Nanoparticles for Treating Primary Orthotopic Colon Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Guoliang Liu ◽  
Min Wang ◽  
Hongyu He ◽  
Jiannan Li
Keyword(s):  
Colorectal Cancer ◽  
Drug Delivery ◽  
Colon Cancer ◽  
Disulfide Bonds ◽  
Tumor Targeting ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Antitumor Properties ◽  
Targeting Peptide ◽  
Tumor Targeting Peptide

Colorectal cancer is the third most common malignant disease worldwide, and chemotherapy has been the standard treatment for colorectal cancer. However, the therapeutic effects of chemotherapy are unsatisfactory for advanced and recurrent colorectal cancers. Thus, increasing the treatment efficacy of chemotherapy in colorectal cancer is a must. In this study, doxorubicin (DOX)-loaded tumor-targeting peptide-decorated mPEG-P(Phe-co-Cys) nanoparticles were developed to treat orthotopic colon cancer in mice. The peptide VATANST (STP) can specifically bind with vimentin highly expressed on the surface of colon cancer cells, thus achieving the tumor-targeting effects. The nanoparticles are core-shell structured, which can protect the loaded DOX while passing through the blood flow and increase the circulation time. The disulfide bonds within the nanoparticles are sensitive to the glutathione-rich microenvironment of tumor tissues. Rupture of disulfide bonds of the nanoparticles leads to the continuous release of DOX, thus resulting in the apoptosis of the tumor cells. The in vivo experiments in mice with orthotopic colon cancer demonstrated that the synthesized DOX-loaded tumor-targeting peptide-decorated polypeptide nanoparticles showed properties of drug delivery systems and exhibited good antitumor properties. The synthesized nanoparticles show appropriate properties as one of the drug delivery systems and exhibit good antitumor properties after encapsulating DOX.

Sign in / Sign up

Export Citation Format

Share Document